Understanding the impact of multimorbidity on chronic airway diseases

Chronic Airway Disease and Multimorbidity (CAM) Cohort: Protocol of a Prospective Multicenter Observational Cohort Study

This study looks at how having multiple health issues affects people with chronic lung diseases like COPD, asthma, or bronchiectasis to help improve their care and treatment.

Quick facts

• Study type: Observational
• Enrollment: 2000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: China-Japan Friendship Hospital (other)
• Locations: 9 sites (Beijing, Beijing Municipality and 8 other locations)
• Trial ID: NCT06798077 on ClinicalTrials.gov

What this trial studies

The Chronic Airway Disease and Multimorbidity (CAM) Cohort is a nationwide, prospective, multicenter observational study that aims to recruit at least 2,000 patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD), asthma, or bronchiectasis. The study will collect comprehensive data on demographics, medical history, comorbidities, lung function, and quality of life during hospitalization and follow up with participants for one year post-discharge. By analyzing how multimorbidity affects treatment outcomes and healthcare utilization, the study seeks to provide insights into the management of chronic airway diseases.

Who should consider this trial

Good fit: Ideal candidates for this study are patients aged 40 and older with chronic obstructive pulmonary disease or those aged 18 and older with asthma or bronchiectasis experiencing an acute exacerbation.

Not a fit: Patients with a life expectancy of less than one month or those with certain lung diseases like cystic fibrosis or interstitial lung disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies and better health outcomes for patients with chronic airway diseases and multimorbidity.

How similar studies have performed: While the impact of multimorbidity on chronic airway diseases is underexplored, similar observational studies have shown promise in understanding the complexities of comorbid conditions.

Eligibility criteria

Inclusion Criteria:

* Patients with chronic obstructive pulmonary disease ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age;
* The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis".

Exclusion Criteria:

* Patients were unable to undergo spirometry during the stabilization period;
* Expected survival is less than 1 month;
* Refusal to sign an informed consent form;
* Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion;
* Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation.

Where this trial is running

Beijing, Beijing Municipality and 8 other locations

• National Center for Respiratory Medicine, China-Japan Friendship Hospital — Beijing, Beijing Municipality, China (RECRUITING)
• Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (RECRUITING)
• Henan Provincial People's Hospital — Zhengzhou, Henan, China (RECRUITING)
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (RECRUITING)
• The Second Xiangya Hospital of Central South University — Changsha, Hunan, China (RECRUITING)
• The First Affiliated Hospital of China Medical University — Shenyang, Liaoning, China (RECRUITING)
• The Second Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi, China (RECRUITING)
• Ruijin Hospital Affiliated to Shanghai Jiao Tong University — Shanghai, Shanghai Municipality, China (RECRUITING)
• West China Hospital of Sichuan University — Chengdu, Sichuan, China (RECRUITING)

Study contacts

• Principal investigator: Ting Yang, MD — China-Japan Friendship Hospital, National Center for Respiratory Medicine
• Study coordinator: Ke Huang, MD.

Conditions: Chronic Obstructive Pulmonary Disease, Asthma, Bronchiectasis, multimorbidity, COPD, asthma, bronchiectasis, exacerbation